Latest news on Vebreltinib drug donation policy

Vebreltinib/vebreltinib, as a domestically independently developed targeted drug, has attracted great attention from clinical and non-small cell lung cancer (NSCLC) patients in recent years. As it is launched in China and gradually enters the medical insurance catalog, how to further reduce the financial burden on patients has become a key topic of social concern. As an important supplementary measure for drug accessibility, the drug donation policy has always been a common way to promote innovative drugs. According to the latest industry trends and public information, the drug donation policy for bricitinib has been gradually implemented in some regions or cooperation channels to provide patients with more humane medication support.

Looking at the overall trend,britinib’s drug donation model is usually closely integrated with the patient assistance program (PAP). Such projects are generally promoted by pharmaceutical companies and public welfare organizations in order to further reduce the burden on patients in addition to medical insurance reimbursement. In terms of specific form, it may adopt the model of "buy a few and get a few free" or "free medicine after the first purchase". For example, after a patient completes the purchase of the first cycle of treatment, he or she can receive additional free medicines based on treatment needs, thus extending the treatment time and reducing direct expenditures. This policy not only helps patients adhere to standard treatment, but also improves clinical compliance with medications.

It is worth noting that the drug donation policy is not uniform across the country and is usually affected by the results of regional medical insurance negotiations, local hospital cooperation and corporate market strategies. It is easier for tertiary hospitals in some large cities or medical institutions with national drug assistance project resources to take the lead in launching bricitinib donation programs. In some grassroots areas, relevant policies may not yet be covered. Therefore, patients need to confirm specific assistance channels with their doctor or hospital pharmacy department when seeking medical treatment.

In addition, as a domestically developed innovative drug, the price of briboritinib is already more affordable than similar imported drugs. In addition, the proportion of patients paying out-of-pocket after medical insurance reimbursement is further reduced, and the implementation of the drug donation policy makes the overall treatment cost further controllable.

Reference materials:https://www.asymbio.com.cn/